PMID- 12517360
OWN - NLM
STAT- MEDLINE
DCOM- 20030129
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 113
IP  - 9
DP  - 2002 Dec 15
TI  - Use of cytosolic and myofibril markers in the detection of ongoing myocardial 
      damage in patients with chronic heart failure.
PG  - 717-22
AB  - PURPOSE: Measurement of serum levels of cytosolic and myofibril components of 
      cardiac tissue could indicate ongoing myocardial damage in patients with chronic 
      heart failure. METHODS: We correlated serum levels of a cytosolic marker 
      (heart-type fatty acid-binding protein) and a myofibril marker (troponin T) with 
      the severity of symptoms (based on the New York Heart Association [NYHA] class), 
      neurohumoral derangement, and subsequent cardiac events in 56 patients with 
      chronic heart failure. RESULTS: Mean (+/- SD) levels of heart-type fatty 
      acid-binding protein were greater in patients with NYHA class III or IV heart 
      failure (9.9 +/- 5.2 ng/mL) than in those with NYHA class II (4.9 +/- 1.9 ng/mL, 
      P <0.0001). Detection of troponin T (> or =0.02 ng/mL) was also more common in 
      patients with worse heart failure (81% [13/16] in class III or IV vs. 43% [17/40] 
      in class II, P = 0.02). Significant correlations were found between heart-type 
      fatty acid-binding protein levels and plasma levels of A-type natriuretic peptide 
      (r = 0.45, P = 0.0004), B-type natriuretic peptide (r = 0.66, P <0.0001), and 
      norepinephrine (r = 0.36, P = 0.006). Male sex (hazard ratio [HR] = 5.0; 95% 
      confidence interval [CI]: 1.3 to 19), detectable troponin T levels (HR = 7.0; 95% 
      CI: 1.1 to 44), heart-type fatty acid-binding protein (HR = 2.6 per 3.9-ng/mL 
      increase; 95% CI: 1.1 to 6.5), and left ventricular ejection fraction (HR = 3.6 
      per 15% decrease; 95% CI: 1.2 to 11) were independently associated with 
      subsequent cardiac events (8 deaths or 10 readmissions because of worsening heart 
      failure). CONCLUSION: Heart-type fatty acid-binding protein and troponin T are 
      markers of ongoing myocardial damage, and are associated with subsequent cardiac 
      events in patients with chronic heart failure.
FAU - Setsuta, Koichi
AU  - Setsuta K
AD  - Division of Cardiology, Department of Internal Medicine, Tokyo Metropolitan 
      Komagome Hospital, Tokyo, Japan.
FAU - Seino, Yoshihiko
AU  - Seino Y
FAU - Ogawa, Takeshi
AU  - Ogawa T
FAU - Arao, Masato
AU  - Arao M
FAU - Miyatake, Yoshiko
AU  - Miyatake Y
FAU - Takano, Teruo
AU  - Takano T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Carrier Proteins)
RN  - 0 (FABP7 protein, human)
RN  - 0 (Fatty Acid-Binding Protein 7)
RN  - 0 (Fatty Acid-Binding Proteins)
RN  - 0 (Fatty Acids)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Troponin T)
RN  - 0 (Tumor Suppressor Proteins)
SB  - IM
MH  - Aged
MH  - Carrier Proteins/*blood
MH  - Case-Control Studies
MH  - Fatty Acid-Binding Protein 7
MH  - Fatty Acid-Binding Proteins
MH  - Fatty Acids/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/blood/*diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardium/metabolism/pathology
MH  - *Neoplasm Proteins
MH  - Time Factors
MH  - Troponin T/*blood
MH  - *Tumor Suppressor Proteins
EDAT- 2003/01/09 04:00
MHDA- 2003/01/30 04:00
CRDT- 2003/01/09 04:00
PHST- 2003/01/09 04:00 [pubmed]
PHST- 2003/01/30 04:00 [medline]
PHST- 2003/01/09 04:00 [entrez]
AID - S0002934302013943 [pii]
AID - 10.1016/s0002-9343(02)01394-3 [doi]
PST - ppublish
SO  - Am J Med. 2002 Dec 15;113(9):717-22. doi: 10.1016/s0002-9343(02)01394-3.